2026 — Gowri Gopal — FM hub genes AGT, SNCA, EZH2 + estrogen-pathway dysregulation

One-paragraph summary

Bioinformatics analysis of FM-associated gene-expression data with protein-protein interaction (PPI) network analysis identifying differentially expressed genes (DEGs). Key empirical findings: 1050 DEGs identified; three hub genes emerge as potential key regulators — AGT (angiotensinogen, renin-angiotensin system, involved in blood pressure regulation, electrolyte balance, neuroinflammatory processes); SNCA (α-synuclein, synaptic dysfunction, central sensitization); EZH2 (epigenetic regulator, gene expression modulation in pain sensitization and neuroinflammation). Hub genes show association with established FM pain targets BDNF, TAC1, and NGF. Connections inferred (literature-based, not directly measured) with neuropathic-pain genes in mPFC, NAc, and PAG brain regions. Stress-hormone connections suggested for cortisol, dopamine, and serotonin pathways. Estrogen-pathway signal: ESR2 (estrogen receptor β) downregulated, ABHD2 downregulated, SULT1E1 (estrogen sulfotransferase) upregulated — coherent picture of altered estrogen metabolism, particularly relevant in postmenopausal women. For the project, this paper extends Hypothesis 2's heritable neural predictive-coding substrate (currently anchored at the GWAS layer by Kerrebijn 2025, 2.5M individuals, brain-tissue-exclusive heritability) into FM-specific transcriptome territory. The hub genes AGT, SNCA, and EZH2 are not in the project ontology yet; the ESR2/ABHD2/SULT1E1 estrogen-pathway gene set provides molecular substrate for the Wang 2025 estrogen-mast-cell bridge at the transcriptomic level. Bioinformatics-only — claims about brain-region effects are inferential.

Claims as triples

• AGT — hub_gene_for → fm_central_only [evidence: identified via PPI network analysis of 1050 DEGs; confidence: emerging]
• SNCA — hub_gene_for → fm_central_only [evidence: same PPI analysis, associated with synaptic dysfunction; confidence: emerging]
• EZH2 — hub_gene_for → fm_central_only [evidence: same PPI analysis, epigenetic regulator; confidence: emerging]
• hub_genes — associate_with → BDNF [evidence: PPI connections to known FM pain target; confidence: emerging]
• hub_genes — associate_with → central_sensitization [evidence: SNCA-synaptic-dysfunction inference + EZH2-pain-sensitization-modulation inference; confidence: bridging]
• estrogen_pathway_dysregulation — present_in → fm_central_only [evidence: ESR2↓, ABHD2↓, SULT1E1↑ in DEG analysis; confidence: emerging]
• EZH2 — candidate → therapeutic_target [evidence: paper's framing as druggable epigenetic regulator; confidence: emerging]

Triangulation notes

• Extends Kerrebijn 2025 GWAS at the transcriptome layer. Kerrebijn establishes exclusive brain-tissue heritability enrichment at the GWAS level; Gowri Gopal supplies a specific FM-transcriptome hub-gene set that operationalizes the neural-substrate hypothesis at the molecular level. AGT, SNCA, EZH2 are new gene-substrate candidates.
• Provides molecular substrate for the Wang 2025 estrogen-MC bridge. Wang 2025 documented an estrogen-mast-cell molecular bridge as a hormonal modifier of Hypothesis 3's downstream effector arm; Gowri Gopal supplies a coherent estrogen-metabolism transcriptome pattern (ESR2↓, ABHD2↓, SULT1E1↑) that anchors the bridge at the FM gene-expression layer.
• SNCA → α-synuclein → Parkinson's biology cross-condition implication. SNCA as an FM hub gene is novel; α-synuclein is the Parkinson's-disease aggregation-prone protein. This is a potential candidate cross-condition bridge worth tracking (FM-Parkinson's synaptic dysfunction).
• AGT (renin-angiotensin system) cross-condition implication. AGT links FM molecular biology to RAS pharmacology. Several FM-comorbid cardiovascular conditions (POTS, autonomic dysfunction) involve RAS components. Worth tracking as a cure-path-arm cross-pharmacology candidate (ACE inhibitors, ARBs already FDA-approved; cheap repurposing-tier).
• EZH2 as candidate therapeutic target — EZH2 inhibitors are clinical-stage drugs in oncology (tazemetostat, FDA-approved 2020 for epithelioid sarcoma). Tracking as a candidate advanced-therapy / repurposing-tier candidate, though oncology dosing and safety profile would need substantial adaptation for chronic-pain population.
• Bioinformatics-only limitation. Brain-region effects (mPFC, NAc, PAG) are inferred from literature, not directly measured. Hub-gene candidacy should be considered emerging until validated in animal models or human histology.

Open questions raised

• Do AGT-related cardiovascular medications (ACEi, ARB classes) modify FM phenotype in retrospective EHR analyses?
• Does the SNCA-FM-association replicate in FM brain tissue (post-mortem) or animal-model proteomics?
• Would EZH2 inhibitors (tazemetostat at sub-oncology dose, or experimental EZH2-degraders) interrupt the central-sensitization pain phenotype in FM animal models?
• Does the estrogen-pathway gene-expression pattern (ESR2↓, ABHD2↓, SULT1E1↑) replicate in the postmenopausal-FM subset specifically?
• Are AGT, SNCA, EZH2 SNP variants enriched in the Kerrebijn 2025 GWAS top loci?